The University actively supports entrepreneurs and academic staff in the creation of new ventures to lead the exploitation of research generated opportunities. This support ranges from licensing IP to start-ups to directly supporting the planning/ formation of a spin-out venture. Since 2006, the University has had a partnership with leading early-stage investor - IP Group plc who provide expertise in company creation and access to investment.
More information about our approach to Intellectual Property and Commercialisation can be found in our policies.
If you are interested in finding out more about our pipeline of spinout companies and how you could get involved please contact Melville Anderson, Head of IP & Commercialisation.
University of Glasgow - Venture Portfolio
Intense uses propietary Quantum Well Intermixing (QWI) technology and manufacturing processes to create diode laser products with unrivalled levels of power, brightness and reliability for range of markets.
CroninGroupPLC is a discovery company focused on developing a number of projects targeting important new chemicals, materials, formulations and pharmaceuticals in important commercial areas. We are developing the ChemputerTM, an autonomous universal digital synthesis engine, which intends to open up chemistry to a wide user-base via digitization. This will allow chemical synthesis to be flexible and widely accessible irrespective of access to physical infrastructure and chemical knowledge.
Thermoelectric Conversion Systems Ltd is a UK high technology SME who design, manufacture and sell electronic power converters, test equipment, educational products and services for use with thermoelectric power generation and cooling devices with a core competency in energy recovery from waste heat.
Causeway Therapeutics Ltd is developing a microRNA therapy for the treatment of tendinopathy in human ( TenoMiR TM) and equine (EquiMiR TM) patients. A ground breaking discovery of a single microRNA-dependent regulatory pathway in early tissue healing highlights a microRNA replacement therapy as a promising therapeutic option for human and equine tendon representing a major advance in patient and animal care.
Saw Dx is an emerging point of care diagnostic (POCD) device design and manufacture venture focussed on exploiting Acoustic-Flow technology.
Clyde Biosciences is a pre-clinical contract research organisation which provides new instrumentation and services for cell-based (including stem cell) testing for early detection of toxicity in drug discovery.
Acquired by Airwave:
Acquired by Avacta:
Acquired by Gemfire: